{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:02:45Z","timestamp":1792785765891,"version":"4.5.0"},"reference-count":11,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013342","name":"Imperial Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013342","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Institute for Diabetes and Digestive and Kidney Disorders, the Cystic Fibrosis Foundation","id":[{"id":"https:\/\/ror.org\/00ax59295","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,1]]},"DOI":"10.1093\/ajrccm\/aamag412","type":"journal-article","created":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T11:34:48Z","timestamp":1786275288000},"page":"2518-2519","source":"Crossref","is-referenced-by-count":0,"title":["Cystic fibrosis in 2026: game over, or game on? Introduction to an\n                    <i>AJRCCM<\/i>\n                    special section on cystic fibrosis"],"prefix":"10.1093","volume":"212","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6756-9822","authenticated-orcid":false,"given":"Andrew","family":"Bush","sequence":"first","affiliation":[{"name":"National Heart and Lung Institute, Imperial College, and Imperial Centre for Paediatrics and Child Health , London,","place":["United Kingdom"]},{"name":"Pediatric Respiratory Medicine, Royal Brompton Hospital , London,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Washington School of Medicine , Seattle, WA,","place":["United States"]},{"name":"Center for Respiratory Biology and Therapeutics, Seattle Children\u2019s Research Institute , Seattle, WA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"2026093006125453000_aamag412-B1","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.3390\/jcm15051933","article-title":"Antenatal CFTR modulators to treat a healthy pregnant woman with a fetus affected by cystic fibrosis complicated by meconium ileus and intestinal volvulus: from a suspicion of the disease to a targeted treatment in utero: case report and narrative review","volume":"15","author":"Montironi","year":"2026","journal-title":"J Clin Med"},{"key":"2026093006125453000_aamag412-B2","doi-asserted-by":"publisher","first-page":"S1569-1993(26)00055-X","DOI":"10.1016\/j.jcf.2026.03.010","article-title":"Mucus and inflammation in the HEMT era: persistent barriers to complete airway normalization in cystic fibrosis","author":"Ehre","year":"2026","journal-title":"J Cyst Fibros"},{"key":"2026093006125453000_aamag412-B3","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1164\/rccm.202412-2431VP","article-title":"Stop the asthma treatment elevator, we need to get off!","volume":"211","author":"Bush","year":"2025","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006125453000_aamag412-B4","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.jcf.2024.04.013","article-title":"Heterogeneity in response to elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis","volume":"23","author":"Alicandro","year":"2024","journal-title":"J Cyst Fibros"},{"key":"2026093006125453000_aamag412-B5","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1056\/NEJMp2517624","article-title":"Can AI say \u201cI don\u2019t know\u201d?","volume":"394","author":"Sikora","year":"2026","journal-title":"N Engl J Med"},{"key":"2026093006125453000_aamag412-B6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1378\/chest.12-1430","article-title":"Change in sweat chloride as a clinical end point in cystic fibrosis clinical trials: the ivacaftor experience","volume":"143","author":"Durmowicz","year":"2013","journal-title":"Chest"},{"key":"2026093006125453000_aamag412-B7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/ajrccm\/aamaf001","article-title":"Elexacaftor\/tezacaftor\/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study","volume":"212","author":"Castellani","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006125453000_aamag412-B8","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/ajrccm\/aamaf102","article-title":"CFTR modulators and rare variants-leaping from laboratory cells to real world effectiveness?","volume":"212","author":"Simmonds","year":"2026","journal-title":"Am J Respir Crit Care Med"},{"key":"2026093006125453000_aamag412-B9","doi-asserted-by":"publisher","first-page":"2202437","DOI":"10.1183\/13993003.02437-2022","article-title":"The French compassionate programme of elexacaftor\/tezacaftor\/ivacaftor in people with cystic fibrosis with advanced lung disease and no F508del CFTR variant","volume":"61","author":"Burgel","year":"2023","journal-title":"Eur Respir J"},{"key":"2026093006125453000_aamag412-B10","doi-asserted-by":"publisher","first-page":"00701","DOI":"10.1183\/23120541.00701-2024","article-title":"Efficacy and safety of CFTR modulators in patients with interstitial lung disease caused by ABCA3 transporter deficiency","volume":"11","author":"Le Brun","year":"2025","journal-title":"ERJ Open Res"},{"key":"2026093006125453000_aamag412-B11","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.molmed.2022.11.001","article-title":"ABC transporters: human disease and pharmacotherapeutic potential","volume":"29","author":"Moore","year":"2023","journal-title":"Trends Mol Med"}],"container-title":["American Journal of Respiratory and Critical Care Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajrccm\/advance-article-pdf\/doi\/10.1093\/ajrccm\/aamag412\/70603118\/aamag412.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/212\/10\/2518\/70603118\/aamag412.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajrccm\/article-pdf\/212\/10\/2518\/70603118\/aamag412.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:13:01Z","timestamp":1790763181000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajrccm\/article\/212\/10\/2518\/8758325"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":11,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,8,10]]},"published-print":{"date-parts":[[2026,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ajrccm\/aamag412","relation":{},"ISSN":["1535-4970"],"issn-type":[{"value":"1535-4970","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,8,10]]}}}